CRSP

SEC source: 0000899243-20-026296 · doc4.xml · nonDerivative · entry 2

Bolzon Bradley J PhD · CIK 0001354345 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 84,544

F3 · kind: Represents a change in the form of ownership of VV IV by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VVC IV.

F4 · ownership.nature: Shares held of record by VV IV. The Reporting Person is a managing director of VV IV and may be deemed to indirectly beneficially own the securities through his interest in VV IV. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any.

SEC source: 0000899243-20-026296 · doc4.xml · nonDerivative · entry 1

Bolzon Bradley J PhD · CIK 0001354345 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 1,746,493

F1 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Venture Capital IV, L.P. ("VVC IV"), to its partners, pursuant to a Rule 10b5-1 distribution plan.

F2 · ownership.nature: These securities are held of record by VVC IV. Versant Ventures IV, LLC ("VV IV") is the sole general partner of VVC IV and may be deemed to have voting and investment power over the securities held by VVC IV and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV IV and may be deemed to indirectly beneficially own the securities through his interest in VV IV. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any.

SEC source: 0000899243-20-025969 · doc4.xml · nonDerivative · entry 1

Bolzon Bradley J PhD · CIK 0001354345 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 518,190

F1 · kind: The sale of these securities was affected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F2 · shares: These securities are held of record by Versant Venture Management, LLC ("VVM LLC"), for the benefit of the Reporting Person, pursuant to an agreement between VVM LLC and the Reporting Person.

F3 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $86.85 to $86.98, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.

F4 · ownership.nature: These securities are held of record by VVM LLC. The Reporting Person is a managing member of VVM LLC and the Reporting Person may be deemed to indirectly beneficially own the securities through his interest in VVM LLC. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any.

SEC source: 0000899243-20-025722 · doc4.xml · nonDerivative · entry 1

Bolzon Bradley J PhD · CIK 0001354345 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 521,225

F1 · kind: The sale of these securities was affected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F2 · shares: These securities are held of record by Versant Venture Management, LLC ("VVM LLC"), for the benefit of the Reporting Person, pursuant to an agreement between VVM LLC and the Reporting Person.

F3 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $86.85 to $87.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.

F4 · ownership.nature: These securities are held of record by VVM LLC. The Reporting Person is a managing member of VVM LLC and the Reporting Person may be deemed to indirectly beneficially own the securities through his interest in VVM LLC. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any.

SEC source: 0000899243-20-025417 · doc4.xml · nonDerivative · entry 1

Bolzon Bradley J PhD · CIK 0001354345 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 530,190

F1 · kind: The sale of these securities was affected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F2 · shares: These securities are held of record by Versant Venture Management, LLC ("VVM LLC"), for the benefit of the Reporting Person, pursuant to an agreement between VVM LLC and the Reporting Person.

F3 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $84.85 to $84.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.

F4 · ownership.nature: These securities are held of record by VVM LLC. The Reporting Person is a managing member of VVM LLC and the Reporting Person may be deemed to indirectly beneficially own the securities through his interest in VVM LLC. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any.

SEC source: 0000899243-20-024943 · doc4.xml · nonDerivative · entry 7

Bolzon Bradley J PhD · CIK 0001354345 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 531,345

F9 · kind: The sale of these securities was affected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F10 · shares: These securities are held of record by Versant Venture Management, LLC ("VVM LLC"), for the benefit of the Reporting Person, pursuant to an agreement between VVM LLC and the Reporting Person.

F13 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $85.50 to $86.47, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (13) to this Form 4.

F12 · ownership.nature: These securities are held of record by VVM LLC. The Reporting Person is a managing member of VVM LLC and the Reporting Person may be deemed to indirectly beneficially own the securities through his interest in VVM LLC. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any.

SEC source: 0000899243-20-024943 · doc4.xml · nonDerivative · entry 6

Bolzon Bradley J PhD · CIK 0001354345 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 540,029

F9 · kind: The sale of these securities was affected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F10 · shares: These securities are held of record by Versant Venture Management, LLC ("VVM LLC"), for the benefit of the Reporting Person, pursuant to an agreement between VVM LLC and the Reporting Person.

F11 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $84.50 to $85.49, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (11) to this Form 4.

F12 · ownership.nature: These securities are held of record by VVM LLC. The Reporting Person is a managing member of VVM LLC and the Reporting Person may be deemed to indirectly beneficially own the securities through his interest in VVM LLC. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any.

SEC source: 0000899243-20-024943 · doc4.xml · nonDerivative · entry 5

Bolzon Bradley J PhD · CIK 0001354345 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,391

F8 · kind: Represents a change in the form of ownership of the Reporting Person by virtue of the receipt of securities as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by VV IV.

SEC source: 0000899243-20-024943 · doc4.xml · nonDerivative · entry 4

Bolzon Bradley J PhD · CIK 0001354345 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

F7 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VV IV to its members.

F6 · ownership.nature: These securities are held of record by VV IV. The Reporting Person is a managing director of VV IV and may be deemed to indirectly beneficially own the securities through his interest in VV IV. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any.

SEC source: 0000899243-20-024943 · doc4.xml · nonDerivative · entry 3

Bolzon Bradley J PhD · CIK 0001354345 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 42,272

F5 · kind: Represents a change in the form of ownership of VV IV, by virtue of the receipt of securities as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by VVC IV.

F6 · ownership.nature: These securities are held of record by VV IV. The Reporting Person is a managing director of VV IV and may be deemed to indirectly beneficially own the securities through his interest in VV IV. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any.

SEC source: 0000899243-20-024943 · doc4.xml · nonDerivative · entry 2

Bolzon Bradley J PhD · CIK 0001354345 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 12,303

F3 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Side Fund IV, L.P. ("VSF IV"), to its partners.

F4 · ownership.nature: These securities are held of record by VSF IV. VV IV is the sole general partner of VSF IV and may be deemed to have voting and investment power over the securities held by VSF IV and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV IV and may be deemed to indirectly beneficially own the securities through his interest in VV IV. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any.

SEC source: 0000899243-20-024943 · doc4.xml · nonDerivative · entry 1

Bolzon Bradley J PhD · CIK 0001354345 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 2,074,817

F1 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Venture Capital IV, L.P. ("VVC IV"), to its partners.

F2 · ownership.nature: These securities are held of record by VVC IV. Versant Ventures IV, LLC ("VV IV") is the sole general partner of VVC IV and may be deemed to have voting and investment power over the securities held by VVC IV and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV IV and may be deemed to indirectly beneficially own the securities through his interest in VV IV. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any.

SEC source: 0001209191-20-049421 · doc4.xml · nonDerivative · entry 1

Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 169,968

F1 · kind: On December 1, 2017, the reporting person was granted 26,667 restricted stock units. On September 1, 2020, 1,667 restricted stock units vested. Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.

SEC source: 0000899243-20-024201 · doc4.xml · derivative · entry 17

Bolzon Bradley J PhD · CIK 0001354345 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 15,000

Underlying: Common Shares · 15,000 shares

Expires 2028-06-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F12 · shares: These options are held of record by Mr. Woiwode. Each of the Reporting Person and Mr. Woiwode are managing members of VVM LLC. Pursuant to agreements with VVM LLC, Mr. Woiwode is deemed to hold these securities for the benefit of VVM LLC. Accordingly, VVM LLC may be deemed to be the indirect beneficial owner of these securities, and the Reporting Person may be deemed to indirectly beneficially own the securities through his interest in VVM LLC. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein.

F16 · derivative.exercise_date: This option was granted on June 15, 2018 with 100% of the shares vesting in 12 equal monthly installments beginning on May 30, 2018.

F14 · balance_after: These options are held of record by the Reporting Person. The Reporting Person is a managing member of VVM LLC. Pursuant to agreements with VVM LLC, the Reporting Person is deemed to hold these securities for the benefit of VVM LLC. Accordingly, VVM LLC may be deemed to be the indirect beneficial owner of these securities, and the Reporting Person may be deemed to indirectly beneficially own the securities through his interest in VVM LLC. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein.

F12 · ownership.nature: These options are held of record by Mr. Woiwode. Each of the Reporting Person and Mr. Woiwode are managing members of VVM LLC. Pursuant to agreements with VVM LLC, Mr. Woiwode is deemed to hold these securities for the benefit of VVM LLC. Accordingly, VVM LLC may be deemed to be the indirect beneficial owner of these securities, and the Reporting Person may be deemed to indirectly beneficially own the securities through his interest in VVM LLC. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein.

F14 · ownership.nature: These options are held of record by the Reporting Person. The Reporting Person is a managing member of VVM LLC. Pursuant to agreements with VVM LLC, the Reporting Person is deemed to hold these securities for the benefit of VVM LLC. Accordingly, VVM LLC may be deemed to be the indirect beneficial owner of these securities, and the Reporting Person may be deemed to indirectly beneficially own the securities through his interest in VVM LLC. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein.

SEC source: 0000899243-20-024201 · doc4.xml · derivative · entry 16

Bolzon Bradley J PhD · CIK 0001354345 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 15,000

Underlying: Common Shares · 15,000 shares

Expires 2027-05-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F12 · shares: These options are held of record by Mr. Woiwode. Each of the Reporting Person and Mr. Woiwode are managing members of VVM LLC. Pursuant to agreements with VVM LLC, Mr. Woiwode is deemed to hold these securities for the benefit of VVM LLC. Accordingly, VVM LLC may be deemed to be the indirect beneficial owner of these securities, and the Reporting Person may be deemed to indirectly beneficially own the securities through his interest in VVM LLC. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein.

F15 · derivative.exercise_date: This option was granted on May 31, 2017 with 100% of the shares vesting in 12 equal monthly installments beginning June 30, 2017.

F14 · balance_after: These options are held of record by the Reporting Person. The Reporting Person is a managing member of VVM LLC. Pursuant to agreements with VVM LLC, the Reporting Person is deemed to hold these securities for the benefit of VVM LLC. Accordingly, VVM LLC may be deemed to be the indirect beneficial owner of these securities, and the Reporting Person may be deemed to indirectly beneficially own the securities through his interest in VVM LLC. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein.

F12 · ownership.nature: These options are held of record by Mr. Woiwode. Each of the Reporting Person and Mr. Woiwode are managing members of VVM LLC. Pursuant to agreements with VVM LLC, Mr. Woiwode is deemed to hold these securities for the benefit of VVM LLC. Accordingly, VVM LLC may be deemed to be the indirect beneficial owner of these securities, and the Reporting Person may be deemed to indirectly beneficially own the securities through his interest in VVM LLC. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein.

F14 · ownership.nature: These options are held of record by the Reporting Person. The Reporting Person is a managing member of VVM LLC. Pursuant to agreements with VVM LLC, the Reporting Person is deemed to hold these securities for the benefit of VVM LLC. Accordingly, VVM LLC may be deemed to be the indirect beneficial owner of these securities, and the Reporting Person may be deemed to indirectly beneficially own the securities through his interest in VVM LLC. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein.

SEC source: 0000899243-20-024201 · doc4.xml · derivative · entry 15

Bolzon Bradley J PhD · CIK 0001354345 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 30,000

Underlying: Common Shares · 30,000 shares

Expires 2026-10-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F12 · shares: These options are held of record by Mr. Woiwode. Each of the Reporting Person and Mr. Woiwode are managing members of VVM LLC. Pursuant to agreements with VVM LLC, Mr. Woiwode is deemed to hold these securities for the benefit of VVM LLC. Accordingly, VVM LLC may be deemed to be the indirect beneficial owner of these securities, and the Reporting Person may be deemed to indirectly beneficially own the securities through his interest in VVM LLC. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein.

F13 · derivative.exercise_date: This option was granted on October 18, 2016 with 100% of the shares vesting in 36 equal monthly installments beginning October 31, 2016.

F14 · balance_after: These options are held of record by the Reporting Person. The Reporting Person is a managing member of VVM LLC. Pursuant to agreements with VVM LLC, the Reporting Person is deemed to hold these securities for the benefit of VVM LLC. Accordingly, VVM LLC may be deemed to be the indirect beneficial owner of these securities, and the Reporting Person may be deemed to indirectly beneficially own the securities through his interest in VVM LLC. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein.

F12 · ownership.nature: These options are held of record by Mr. Woiwode. Each of the Reporting Person and Mr. Woiwode are managing members of VVM LLC. Pursuant to agreements with VVM LLC, Mr. Woiwode is deemed to hold these securities for the benefit of VVM LLC. Accordingly, VVM LLC may be deemed to be the indirect beneficial owner of these securities, and the Reporting Person may be deemed to indirectly beneficially own the securities through his interest in VVM LLC. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein.

F14 · ownership.nature: These options are held of record by the Reporting Person. The Reporting Person is a managing member of VVM LLC. Pursuant to agreements with VVM LLC, the Reporting Person is deemed to hold these securities for the benefit of VVM LLC. Accordingly, VVM LLC may be deemed to be the indirect beneficial owner of these securities, and the Reporting Person may be deemed to indirectly beneficially own the securities through his interest in VVM LLC. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein.

SEC source: 0000899243-20-024201 · doc4.xml · nonDerivative · entry 7

Bolzon Bradley J PhD · CIK 0001354345 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

F1 · ownership.nature: These securities are held of record by Thomas Woiwode ("Mr. Woiwode"). Each of the Reporting Person and Mr. Woiwode are managing members of Versant Venture Management, LLC ("VVM LLC"). Pursuant to agreements with VVM LLC, Mr. Woiwode is deemed to hold these securities for the benefit of VVM LLC. Accordingly, VVM LLC may be deemed to be the indirect beneficial owner of these securities, and the Reporting Person may be deemed to indirectly beneficially own the securities through his interest in VVM LLC. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein.

SEC source: 0000899243-20-024201 · doc4.xml · nonDerivative · entry 6

Bolzon Bradley J PhD · CIK 0001354345 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 200

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $92.73 to $93.69, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4.

F1 · ownership.nature: These securities are held of record by Thomas Woiwode ("Mr. Woiwode"). Each of the Reporting Person and Mr. Woiwode are managing members of Versant Venture Management, LLC ("VVM LLC"). Pursuant to agreements with VVM LLC, Mr. Woiwode is deemed to hold these securities for the benefit of VVM LLC. Accordingly, VVM LLC may be deemed to be the indirect beneficial owner of these securities, and the Reporting Person may be deemed to indirectly beneficially own the securities through his interest in VVM LLC. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein.

SEC source: 0000899243-20-024201 · doc4.xml · nonDerivative · entry 5

Bolzon Bradley J PhD · CIK 0001354345 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 19,335

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.73 to $92.725, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.

F1 · ownership.nature: These securities are held of record by Thomas Woiwode ("Mr. Woiwode"). Each of the Reporting Person and Mr. Woiwode are managing members of Versant Venture Management, LLC ("VVM LLC"). Pursuant to agreements with VVM LLC, Mr. Woiwode is deemed to hold these securities for the benefit of VVM LLC. Accordingly, VVM LLC may be deemed to be the indirect beneficial owner of these securities, and the Reporting Person may be deemed to indirectly beneficially own the securities through his interest in VVM LLC. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein.

SEC source: 0000899243-20-024201 · doc4.xml · nonDerivative · entry 4

Bolzon Bradley J PhD · CIK 0001354345 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 55,700

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.73 to $91.72, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.

F1 · ownership.nature: These securities are held of record by Thomas Woiwode ("Mr. Woiwode"). Each of the Reporting Person and Mr. Woiwode are managing members of Versant Venture Management, LLC ("VVM LLC"). Pursuant to agreements with VVM LLC, Mr. Woiwode is deemed to hold these securities for the benefit of VVM LLC. Accordingly, VVM LLC may be deemed to be the indirect beneficial owner of these securities, and the Reporting Person may be deemed to indirectly beneficially own the securities through his interest in VVM LLC. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein.

SEC source: 0000899243-20-024201 · doc4.xml · nonDerivative · entry 3

Bolzon Bradley J PhD · CIK 0001354345 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 60,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · ownership.nature: These securities are held of record by Thomas Woiwode ("Mr. Woiwode"). Each of the Reporting Person and Mr. Woiwode are managing members of Versant Venture Management, LLC ("VVM LLC"). Pursuant to agreements with VVM LLC, Mr. Woiwode is deemed to hold these securities for the benefit of VVM LLC. Accordingly, VVM LLC may be deemed to be the indirect beneficial owner of these securities, and the Reporting Person may be deemed to indirectly beneficially own the securities through his interest in VVM LLC. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein.

SEC source: 0000899243-20-024201 · doc4.xml · nonDerivative · entry 2

Bolzon Bradley J PhD · CIK 0001354345 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 45,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · ownership.nature: These securities are held of record by Thomas Woiwode ("Mr. Woiwode"). Each of the Reporting Person and Mr. Woiwode are managing members of Versant Venture Management, LLC ("VVM LLC"). Pursuant to agreements with VVM LLC, Mr. Woiwode is deemed to hold these securities for the benefit of VVM LLC. Accordingly, VVM LLC may be deemed to be the indirect beneficial owner of these securities, and the Reporting Person may be deemed to indirectly beneficially own the securities through his interest in VVM LLC. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein.

SEC source: 0000899243-20-024201 · doc4.xml · nonDerivative · entry 1

Bolzon Bradley J PhD · CIK 0001354345 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 30,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · ownership.nature: These securities are held of record by Thomas Woiwode ("Mr. Woiwode"). Each of the Reporting Person and Mr. Woiwode are managing members of Versant Venture Management, LLC ("VVM LLC"). Pursuant to agreements with VVM LLC, Mr. Woiwode is deemed to hold these securities for the benefit of VVM LLC. Accordingly, VVM LLC may be deemed to be the indirect beneficial owner of these securities, and the Reporting Person may be deemed to indirectly beneficially own the securities through his interest in VVM LLC. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein.

SEC source: 0001209191-20-049430 · doc4.xml · derivative · entry 5

TOMSICEK MICHAEL JOHN · CIK 0001570392 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 156,000

Underlying: Common Shares · 12,000 shares

Expires 2027-11-21

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: This option was granted on November 13, 2017, 25% of the shares vested on November 13, 2018 and the remaining shares vest in 36 equal monthly installments on the first day of each succeeding calendar month.

SEC source: 0001209191-20-049430 · doc4.xml · nonDerivative · entry 4

TOMSICEK MICHAEL JOHN · CIK 0001570392 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 410

F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $92.82 to $93.74, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

SEC source: 0001209191-20-049430 · doc4.xml · nonDerivative · entry 3

TOMSICEK MICHAEL JOHN · CIK 0001570392 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,210

F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.80 to $92.72, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

SEC source: 0001209191-20-049430 · doc4.xml · nonDerivative · entry 2

TOMSICEK MICHAEL JOHN · CIK 0001570392 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,610

F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.78 to $91.76, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

SEC source: 0001209191-20-049430 · doc4.xml · nonDerivative · entry 1

TOMSICEK MICHAEL JOHN · CIK 0001570392 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,410

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-20-049425 · doc4.xml · derivative · entry 7

Novak Rodger · CIK 0001682017 · Director · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 215,315

Underlying: Common Shares · 21,067 shares

Expires 2027-06-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_date: This option was granted on June 15, 2017 with respect to 270,000 Common Shares and originally vested in 48 equal monthly installments commencing upon the grant date. Pursuant to Dr. Novak's amended and restated employment agreement with the Company, subject to his continued employment, beginning November 30, 2018, the remaining unvested options from this grant vest in equal monthly installments at the rate of 50% of the amounts originally scheduled to vest on any one vesting date, and the original vesting schedule was extended to reflect the amended schedule.

SEC source: 0001209191-20-049425 · doc4.xml · derivative · entry 6

Novak Rodger · CIK 0001682017 · Director · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 111,893

Underlying: Common Shares · 3,933 shares

Expires 2026-10-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: This option was granted on October 18, 2016 with respect to 200,000 Common Shares and originally vested in 48 equal monthly installments beginning October 31, 2016. Pursuant to Dr. Novak's amended and restated employment agreement with the Company, subject to his continued employment, beginning November 30, 2018, the remaining unvested options from this grant vest in equal monthly installments at the rate of 50% of the amounts originally scheduled to vest on any one vesting date, and the original vesting schedule was extended to reflect the amended schedule.

SEC source: 0001209191-20-049425 · doc4.xml · nonDerivative · entry 5

Novak Rodger · CIK 0001682017 · Director · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 648,007

F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $93.005 to $93.81, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

SEC source: 0001209191-20-049425 · doc4.xml · nonDerivative · entry 4

Novak Rodger · CIK 0001682017 · Director · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 651,847

F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.99 to $92.965, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

SEC source: 0001209191-20-049425 · doc4.xml · nonDerivative · entry 3

Novak Rodger · CIK 0001682017 · Director · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 671,601

F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.93 to $91.805, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

SEC source: 0001209191-20-049425 · doc4.xml · nonDerivative · entry 2

Novak Rodger · CIK 0001682017 · Director · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 673,007

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-20-049425 · doc4.xml · nonDerivative · entry 1

Novak Rodger · CIK 0001682017 · Director · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 651,940

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-20-047908 · doc4.xml · derivative · entry 3

Novak Rodger · CIK 0001682017 · Director · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 115,826

Underlying: Common Shares · 25,000 shares

Expires 2026-10-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: This option was granted on October 18, 2016 with respect to 200,000 Common Shares and originally vested in 48 equal monthly installments beginning October 31, 2016. Pursuant to Dr. Novak's amended and restated employment agreement with the Company, subject to his continued employment, beginning November 30, 2018, the remaining unvested options from this grant vest in equal monthly installments at the rate of 50% of the amounts originally scheduled to vest on any one vesting date, and the original vesting schedule was extended to reflect the amended schedule.

SEC source: 0001209191-20-047908 · doc4.xml · nonDerivative · entry 2

Novak Rodger · CIK 0001682017 · Director · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 648,007

F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

SEC source: 0001209191-20-047908 · doc4.xml · nonDerivative · entry 1

Novak Rodger · CIK 0001682017 · Director · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 673,007

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-20-046793 · doc4.xml · nonDerivative · entry 2

Behbahani Ali · CIK 0001613867 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Note 3

Disclosed balance after: 14

F2 · kind: The Ali Behbahani Revocable Trust Dated June 26, 2015 (the "Behbahani Trust") received 14 shares of Common Stock of the Issuer in the distribution by NEA Partners 15 on August 13, 2020.

F3 · ownership.nature: The Reporting Person is the trustee of the Behbahani Trust, which is the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the 1934 Act, as amended, of such portion of the shares of Common Stock of the Issuer held by the Behbahani Trust in which the Reporting Person has no pecuniary interest.

SEC source: 0001209191-20-046793 · doc4.xml · nonDerivative · entry 1

Behbahani Ali · CIK 0001613867 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 256

F1 · kind: NEA Partners 15, L.P. ("NEA Partners 15") made a pro rata distribution for no consideration of shares of Common Stock of the Issuer to its limited partners on August 13, 2020. The Reporting Person received 57 shares of Common Stock of the Issuer in the distribution by NEA Partners 15 on August 13, 2020.

SEC source: 0001209191-20-045100 · doc4.xml · nonDerivative · entry 3

TOMSICEK MICHAEL JOHN · CIK 0001570392 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 410

F2 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.875 to $87.80, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

SEC source: 0001209191-20-045100 · doc4.xml · nonDerivative · entry 2

TOMSICEK MICHAEL JOHN · CIK 0001570392 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,858

F2 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.78 to $86.77, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

SEC source: 0001209191-20-045100 · doc4.xml · nonDerivative · entry 1

TOMSICEK MICHAEL JOHN · CIK 0001570392 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,410

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 410 shares acquired under the CRISPR Therapeutics AG 2016 Employee Stock Purchase Plan.

SEC source: 0000899243-20-018812 · doc4.xml · derivative · entry 5

Novak Rodger · CIK 0001682017 · Director · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 140,826

Underlying: Common Shares · 19,414 shares

Expires 2026-10-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: This option was granted on October 18, 2016 with respect to 200,000 Common Shares and originally vested in 48 equal monthly installments beginning October 31, 2016. Pursuant to Dr. Novak's amended and restated employment agreement with the Company, subject to his continued employment, beginning November 30, 2018, the remaining unvested options from this grant vest in equal monthly installments at the rate of 50% of the amounts originally scheduled to vest on any one vesting date, and the original vesting schedule was extended to reflect the amended schedule.

SEC source: 0000899243-20-018812 · doc4.xml · derivative · entry 4

Novak Rodger · CIK 0001682017 · Director · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 5,586 shares

Expires 2025-09-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: This option was granted on September 10, 2015 with respect to 268,093 Common Shares with 94,950 shares immediately vested on the grant date and the remaining 173,143 shares vesting in 31 equal monthly installments thereafter.

SEC source: 0000899243-20-018812 · doc4.xml · nonDerivative · entry 3

Novak Rodger · CIK 0001682017 · Director · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 648,007

F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

SEC source: 0000899243-20-018812 · doc4.xml · nonDerivative · entry 2

Novak Rodger · CIK 0001682017 · Director · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 673,007

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000899243-20-018812 · doc4.xml · nonDerivative · entry 1

Novak Rodger · CIK 0001682017 · Director · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 653,593

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000899243-20-018703 · doc4.xml · nonDerivative · entry 2

Bolzon Bradley J PhD · CIK 0001354345 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 554,190

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.85 to $83.17, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

F3 · ownership.nature: These securities are held of record by Versant Venture Management, LLC ("VVM LLC"). The Reporting Person is a managing member of VVM LLC and pursuant to agreement with VVM LLC, the Reporting Person is deemed to hold these securities for the benefit of VVM LLC. Accordingly, VVM LLC may be deemed to be the indirect beneficial owner of these securities, and the Reporting Person may be deemed to indirectly beneficially own the securities through his interest in VVM LLC. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest therein.

SEC source: 0000899243-20-018703 · doc4.xml · nonDerivative · entry 1

Bolzon Bradley J PhD · CIK 0001354345 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 559,501

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.85 to $82.83, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

F3 · ownership.nature: These securities are held of record by Versant Venture Management, LLC ("VVM LLC"). The Reporting Person is a managing member of VVM LLC and pursuant to agreement with VVM LLC, the Reporting Person is deemed to hold these securities for the benefit of VVM LLC. Accordingly, VVM LLC may be deemed to be the indirect beneficial owner of these securities, and the Reporting Person may be deemed to indirectly beneficially own the securities through his interest in VVM LLC. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest therein.